Shares of Rubicon Research Ltd., which are trading with gains of over 3% today, can rise as much as 54%, brokerage firm Motilal Oswal projected in its bull-case scenario while initiating coverage on the pharmaceutical company on Friday, October 31.

The brokerage said Rubicon Research is a fast-growing, research and development-driven pharmaceutical manufacturing company focused on regulated markets, particularly the US.

Over the past decade, Rubicon has built a sustainable moat through full-spectrum capabilities across multiple dosage forms, a strong track record in specialty projects, and supporting manufacturing capacities with consistent compliance for US markets.

The company has also maintained a focus on commercial success, the brokerage noted.

Motilal Oswal has initiated coverage

See Full Page